Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. / Asmar, Ali; Simonsen, Lene; Asmar, Meena; Madsbad, Sten; Holst, Jens J; Frandsen, Erik; Moro, Cedric; Sorensen, Charlotte M; Jonassen, Thomas; Bulow, Jens.

I: American Journal of Physiology: Endocrinology and Metabolism, Bind 310, Nr. 9, 05.2016, s. E744-E753.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Asmar, A, Simonsen, L, Asmar, M, Madsbad, S, Holst, JJ, Frandsen, E, Moro, C, Sorensen, CM, Jonassen, T & Bulow, J 2016, 'Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy', American Journal of Physiology: Endocrinology and Metabolism, bind 310, nr. 9, s. E744-E753. https://doi.org/10.1152/ajpendo.00518.2015

APA

Asmar, A., Simonsen, L., Asmar, M., Madsbad, S., Holst, J. J., Frandsen, E., ... Bulow, J. (2016). Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. American Journal of Physiology: Endocrinology and Metabolism, 310(9), E744-E753. https://doi.org/10.1152/ajpendo.00518.2015

Vancouver

Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E o.a. Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. American Journal of Physiology: Endocrinology and Metabolism. 2016 maj;310(9):E744-E753. https://doi.org/10.1152/ajpendo.00518.2015

Author

Asmar, Ali ; Simonsen, Lene ; Asmar, Meena ; Madsbad, Sten ; Holst, Jens J ; Frandsen, Erik ; Moro, Cedric ; Sorensen, Charlotte M ; Jonassen, Thomas ; Bulow, Jens. / Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. I: American Journal of Physiology: Endocrinology and Metabolism. 2016 ; Bind 310, Nr. 9. s. E744-E753.

Bibtex

@article{b136a58a9dfb4b7b972468f868c5dd60,
title = "Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy",
abstract = "During acute administration of native glucagon-like peptide-1 (GLP-1), we previously demonstrated central hemodynamic effects in healthy males, whereas renal hemodynamics, despite renal uptake of GLP-1 in excess of glomerular filtration, was unaffected. In the present study, we studied hemodynamic effects of GLP-1 in patients with type 2 diabetes under fixed sodium intake. During a 3-hour infusion of GLP-1 (1.5 pmol kg(-1) min(-1)) or saline, intra-arterial blood pressure and heart rate were measured continuously, concomitantly with cardiac output estimated by pulse contour analysis. Renal plasma flow, glomerular filtration rate, and uptake/release of hormones and ions were measured using Fick's Principle after catheterization of a renal vein. Urine collection was conducted throughout the experiments at voluntary voiding, and patients remained supine during the experiments. During the GLP-1 infusion, systolic and diastolic blood pressure and cardiac output remained unchanged, whereas heart rate increased significantly. Arterio-venous gradients for GLP-1 exceeded glomerular filtrations significantly, but renal plasma flow and glomerular filtration rate as well as renal sodium and lithium excretion were not affected. In conclusion, acute administration of GLP-1 in patients with type 2 diabetes leads to a positive chronotropic effect, but in contrast to healthy individuals, cardiac output does not increase in patients with type 2 diabetes. Renal hemodynamics and sodium excretion are not affected.",
author = "Ali Asmar and Lene Simonsen and Meena Asmar and Sten Madsbad and Holst, {Jens J} and Erik Frandsen and Cedric Moro and Sorensen, {Charlotte M} and Thomas Jonassen and Jens Bulow",
note = "Copyright {\circledC} 2016, American Journal of Physiology - Endocrinology and Metabolism.",
year = "2016",
month = "5",
doi = "10.1152/ajpendo.00518.2015",
language = "English",
volume = "310",
pages = "E744--E753",
journal = "American Journal of Physiology: Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "9",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy

AU - Asmar, Ali

AU - Simonsen, Lene

AU - Asmar, Meena

AU - Madsbad, Sten

AU - Holst, Jens J

AU - Frandsen, Erik

AU - Moro, Cedric

AU - Sorensen, Charlotte M

AU - Jonassen, Thomas

AU - Bulow, Jens

N1 - Copyright © 2016, American Journal of Physiology - Endocrinology and Metabolism.

PY - 2016/5

Y1 - 2016/5

N2 - During acute administration of native glucagon-like peptide-1 (GLP-1), we previously demonstrated central hemodynamic effects in healthy males, whereas renal hemodynamics, despite renal uptake of GLP-1 in excess of glomerular filtration, was unaffected. In the present study, we studied hemodynamic effects of GLP-1 in patients with type 2 diabetes under fixed sodium intake. During a 3-hour infusion of GLP-1 (1.5 pmol kg(-1) min(-1)) or saline, intra-arterial blood pressure and heart rate were measured continuously, concomitantly with cardiac output estimated by pulse contour analysis. Renal plasma flow, glomerular filtration rate, and uptake/release of hormones and ions were measured using Fick's Principle after catheterization of a renal vein. Urine collection was conducted throughout the experiments at voluntary voiding, and patients remained supine during the experiments. During the GLP-1 infusion, systolic and diastolic blood pressure and cardiac output remained unchanged, whereas heart rate increased significantly. Arterio-venous gradients for GLP-1 exceeded glomerular filtrations significantly, but renal plasma flow and glomerular filtration rate as well as renal sodium and lithium excretion were not affected. In conclusion, acute administration of GLP-1 in patients with type 2 diabetes leads to a positive chronotropic effect, but in contrast to healthy individuals, cardiac output does not increase in patients with type 2 diabetes. Renal hemodynamics and sodium excretion are not affected.

AB - During acute administration of native glucagon-like peptide-1 (GLP-1), we previously demonstrated central hemodynamic effects in healthy males, whereas renal hemodynamics, despite renal uptake of GLP-1 in excess of glomerular filtration, was unaffected. In the present study, we studied hemodynamic effects of GLP-1 in patients with type 2 diabetes under fixed sodium intake. During a 3-hour infusion of GLP-1 (1.5 pmol kg(-1) min(-1)) or saline, intra-arterial blood pressure and heart rate were measured continuously, concomitantly with cardiac output estimated by pulse contour analysis. Renal plasma flow, glomerular filtration rate, and uptake/release of hormones and ions were measured using Fick's Principle after catheterization of a renal vein. Urine collection was conducted throughout the experiments at voluntary voiding, and patients remained supine during the experiments. During the GLP-1 infusion, systolic and diastolic blood pressure and cardiac output remained unchanged, whereas heart rate increased significantly. Arterio-venous gradients for GLP-1 exceeded glomerular filtrations significantly, but renal plasma flow and glomerular filtration rate as well as renal sodium and lithium excretion were not affected. In conclusion, acute administration of GLP-1 in patients with type 2 diabetes leads to a positive chronotropic effect, but in contrast to healthy individuals, cardiac output does not increase in patients with type 2 diabetes. Renal hemodynamics and sodium excretion are not affected.

U2 - 10.1152/ajpendo.00518.2015

DO - 10.1152/ajpendo.00518.2015

M3 - Journal article

VL - 310

SP - E744-E753

JO - American Journal of Physiology: Endocrinology and Metabolism

JF - American Journal of Physiology: Endocrinology and Metabolism

SN - 0193-1849

IS - 9

ER -

ID: 159743705